NO20061072L - Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor - Google Patents

Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor

Info

Publication number
NO20061072L
NO20061072L NO20061072A NO20061072A NO20061072L NO 20061072 L NO20061072 L NO 20061072L NO 20061072 A NO20061072 A NO 20061072A NO 20061072 A NO20061072 A NO 20061072A NO 20061072 L NO20061072 L NO 20061072L
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
reductase inhibitor
dosage forms
cholesterol ester
Prior art date
Application number
NO20061072A
Other languages
English (en)
Inventor
William John Curatolo
Steven Charles Sutton
Dwayne Thomas Friesen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20061072L publication Critical patent/NO20061072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives en doseringsform som omfatter: (a) en kolesterylesteroverføringsproteininhibitor i en oppløselighetsforbedret form, og (b) en HMG-CoA-reduktaseinhibitor; der doseringsformen gir umiddelbar frigivning av nevnte HMG-CoA-reduktaseinhibitor og kontrollert frigivning av nevnte kolesterylestertransferaseproteininhibitor.
NO20061072A 2003-08-04 2006-03-06 Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor NO20061072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49240703P 2003-08-04 2003-08-04
PCT/IB2004/002457 WO2005011634A1 (en) 2003-08-04 2004-07-21 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
NO20061072L true NO20061072L (no) 2006-05-04

Family

ID=34115617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061072A NO20061072L (no) 2003-08-04 2006-03-06 Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor

Country Status (16)

Country Link
US (1) US20050038007A1 (no)
EP (1) EP1653926A1 (no)
JP (1) JP2007501217A (no)
KR (1) KR20060033033A (no)
CN (2) CN1863511A (no)
AR (1) AR045203A1 (no)
AU (1) AU2004261058A1 (no)
BR (1) BRPI0413363A (no)
CA (1) CA2534371A1 (no)
IL (1) IL172875A0 (no)
MX (1) MXPA06001506A (no)
NO (1) NO20061072L (no)
RU (1) RU2006102981A (no)
TW (1) TW200517145A (no)
WO (1) WO2005011634A1 (no)
ZA (2) ZA200600179B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005041869A2 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN1331476C (zh) * 2005-07-05 2007-08-15 凌沛学 一种辅酶a舌下含片及其制备方法
EP1965764B1 (en) 2005-12-05 2011-07-13 Merck Sharp & Dohme Corp. Self-emulsifying formulations of cetp inhibitors
KR100742571B1 (ko) * 2006-03-02 2007-07-25 충남대학교산학협력단 초임계유체 공정을 이용한 무정형 아토르바스타틴 칼슘염및 그 제조방법
CA2612989A1 (en) * 2006-05-08 2007-11-08 Mcneil-Ppc, Inc. Osmotic dosage form
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2008115529A1 (en) * 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
TW201016761A (en) * 2008-10-30 2010-05-01 Univ Nat Taiwan Microporous film and preparation and use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011006066A1 (en) 2009-07-10 2011-01-13 Ironwood Pharmaceuticals, Inc. Cb receptor agonists
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo PROCESS FOR PREPARING OPTICALLY PURE BETA LACTONS FROM ALDEHYDE AND COMPOSITIONS MADE THEREOF
SG181900A1 (en) 2009-12-23 2012-08-30 Ironwood Pharmaceuticals Inc Crth2 modulators
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US8966783B2 (en) * 2010-07-29 2015-03-03 Tanabe Engineering Corporation Vacuum-pressure spray-drying method and vacuum-pressure spray-drying device
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
SE536491C2 (sv) * 2012-03-26 2013-12-27 Bionicotine Ab Påse innehållande nikotin och en tuggummikomposition
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
HK1202445A1 (en) * 2012-04-30 2015-10-02 霍夫曼-拉罗奇有限公司 New formulation
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US20170071930A1 (en) * 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
WO2014100418A2 (en) * 2012-12-20 2014-06-26 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
SG10201805890QA (en) * 2014-01-09 2018-08-30 Verastem Inc Compositions and methods for treatment of abnormal cell growth
US10300059B2 (en) * 2014-08-28 2019-05-28 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
US11180493B2 (en) 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
EA201991147A1 (ru) 2016-11-08 2019-11-29 ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
CN107019927A (zh) * 2017-04-18 2017-08-08 成都绿林科技有限公司 用于药品快速干燥的干燥机
CN109663373A (zh) * 2018-12-26 2019-04-23 无锡市林洲干燥设备有限公司 甲维盐闭式循环喷雾干燥系统
CN110773079B (zh) * 2019-11-18 2022-03-01 江苏博迁新材料股份有限公司 一种超声喷雾法制备超细粉球的方法
CN115724771A (zh) * 2021-08-30 2023-03-03 中国科学院过程工程研究所 一种用于制备n，n’-二苯基脲的装置系统及制备n，n’-二苯基脲的工艺
CN120361800B (zh) * 2025-06-24 2025-09-23 苏州大学 一种基于反溶剂蒸气干燥设备制备亚微米及微米级均一颗粒的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35125A (en) * 1862-04-29 Improvement in spring-balances
US10325A (en) * 1853-12-20 Improvement in manure crushers and sowers
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
ATE226826T1 (de) * 1995-06-01 2002-11-15 Searle & Co Misoprostolhaltige feste stabilisierte dispersionen
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DK1017390T3 (da) * 1997-07-31 2007-06-11 Kos Life Sciences Inc Coated tablet, der omfatter nikotinsyre eller en forbindelse, der metaboliseres til nikotinsyre, i en form med langvarig frigivelse og en HMG-CoA-reduktaseinhibitor i en form med öjeblikkelig frigivelse
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2003002743A0 (en) * 2000-08-15 2003-03-31 Pfizer Prod Inc Therapeutic combination of a cept inhibitor and atorvastatin
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
KR20040011549A (ko) * 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물

Also Published As

Publication number Publication date
JP2007501217A (ja) 2007-01-25
TW200517145A (en) 2005-06-01
BRPI0413363A (pt) 2006-10-10
KR20060033033A (ko) 2006-04-18
WO2005011634A1 (en) 2005-02-10
US20050038007A1 (en) 2005-02-17
EP1653926A1 (en) 2006-05-10
AU2004261058A1 (en) 2005-02-10
ZA200600179B (en) 2007-02-28
ZA200600853B (en) 2007-04-25
CN1863511A (zh) 2006-11-15
MXPA06001506A (es) 2006-05-15
AR045203A1 (es) 2005-10-19
CN1870978A (zh) 2006-11-29
IL172875A0 (en) 2006-06-11
CA2534371A1 (en) 2005-02-10
RU2006102981A (ru) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20061072L (no) Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
DK1727551T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet
DK1727550T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepin-derivat og en inhibitor for RVS-fusions-proteinet
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20052546D0 (no) Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon.
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
CR6883A (es) Composiciones farmaceuticas de inhibidores de la potencia de colesteril ester
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
HN2003000227A (es) Inhibidores de quinasas
NO20052595D0 (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
GT200300023A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
MXPA04003365A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina.
TW200508233A (en) Chk-1 inhibitors
NO20076566L (no) Ny fremgangsmate for behandling av hyperlipidemi
NO20062978L (no) Reduksjon av dermal arrdannelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application